Can-Fite BioPharma Ltd. Net Income Loss

• Can-Fite BioPharma Ltd. showed a decrease of -24.7% in Net Income Loss from 2024 to 2025.
• This data is from Can-Fite BioPharma Ltd.'s annual report (Form 10-K), filed with the SEC on March 26, 2026.
• XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 8 years of available data (2018 to 2025), Can-Fite BioPharma Ltd.'s Net Income Loss has declined by 49.6%.
• Historical annual values: Fiscal year 2025: -$9.83 million | Fiscal year 2024: -$7.88 million | Fiscal year 2023: -$7.63 million | Fiscal year 2022: -$10.17 million | Fiscal year 2021: -$12.62 million | Fiscal year 2020: -$14.44 million | Fiscal year 2019: -$12.63 million | Fiscal year 2018: -$6.57 million.
• Data sourced from SEC EDGAR public filings as of June 20, 2026.

Last verified: June 20, 2026